WallStreetZenWallStreetZen

NASDAQ: ACIU
Ac Immune Sa Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for ACIU

Based on 1 analyst offering 12 month price targets for Ac Immune Sa.
Min Forecast
$10.00+289.11%
Avg Forecast
$10.00+289.11%
Max Forecast
$10.00+289.11%

Should I buy or sell ACIU stock?

Based on 1 analyst offering ratings for Ac Immune Sa.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ACIU stock forecasts and price targets.

ACIU stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
SVB Leerink
Top 6%
95
BuyMaintains$10.00+289.11%2022-07-11

1 of 1

Forecast return on equity

Is ACIU forecast to generate an efficient return?
Company
-13.64%
Industry
13.87%
Market
62.54%
ACIU's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ACIU forecast to generate an efficient return on assets?
Company
-12.61%
Industry
13.22%
ACIU is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ACIU earnings per share forecast

What is ACIU's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$1.01
Avg 2 year Forecast
-$0.33
Avg 3 year Forecast
-$0.33

ACIU revenue forecast

What is ACIU's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$2.5M-38.87%
Avg 2 year Forecast
$86.3M+2,005.83%
Avg 3 year Forecast
$95.3M+2,225.94%
ACIU's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ACIU revenue growth forecast

How is ACIU forecast to perform vs Biotechnology companies and vs the US market?
Company
188.39%
Industry
25.22%
Market
6.79%
ACIU's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ACIU's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ACIU vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACIU$2.57$10.00+289.11%Buy
BLI$3.15$8.33+164.54%Hold
OPT$4.90$34.50+604.08%Strong Buy
IMMP$2.47$8.15+229.96%Strong Buy
RAIN$7.99$17.40+117.77%Strong Buy

Ac Immune Sa Stock Forecast FAQ

Is Ac Immune Sa Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ACIU) stock is to Buy ACIU stock.

Out of 1 analyst, 0 (0%) are recommending ACIU as a Strong Buy, 1 (100%) are recommending ACIU as a Buy, 0 (0%) are recommending ACIU as a Hold, 0 (0%) are recommending ACIU as a Sell, and 0 (0%) are recommending ACIU as a Strong Sell.

If you're new to stock investing, here's how to buy Ac Immune Sa stock.

What is ACIU's earnings growth forecast for 2022-2024?

(NASDAQ: ACIU) Ac Immune Sa's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.82%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.99%.

Ac Immune Sa's earnings in 2022 is -$74,023,232.On average, 3 Wall Street analysts forecast ACIU's earnings for 2022 to be -$85,307,302, with the lowest ACIU earnings forecast at -$88,685,809, and the highest ACIU earnings forecast at -$79,394,915. On average, 3 Wall Street analysts forecast ACIU's earnings for 2023 to be -$27,872,683, with the lowest ACIU earnings forecast at -$79,394,915, and the highest ACIU earnings forecast at $53,211,485.

In 2024, ACIU is forecast to generate -$27,872,683 in earnings, with the lowest earnings forecast at -$87,841,182 and the highest earnings forecast at $13,514,028.

What is ACIU's revenue growth forecast for 2022-2024?

(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 188.39% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 25.22%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 6.79%.

Ac Immune Sa's revenue in 2022 is $3,973,737.On average, 2 Wall Street analysts forecast ACIU's revenue for 2022 to be $211,579,001, with the lowest ACIU revenue forecast at $177,371,618, and the highest ACIU revenue forecast at $245,786,384. On average, 2 Wall Street analysts forecast ACIU's revenue for 2023 to be $7,288,706,539, with the lowest ACIU revenue forecast at $2,250,085,662, and the highest ACIU revenue forecast at $12,327,327,416.

In 2024, ACIU is forecast to generate $8,050,559,868 in revenue, with the lowest revenue forecast at $6,877,795,625 and the highest revenue forecast at $9,223,324,110.

What is ACIU's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: ACIU) forecast ROA is -12.61%, which is lower than the forecast US Biotechnology industry average of 13.22%.

What is ACIU's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ACIU price target, the average ACIU price target is $10.00, with the highest ACIU stock price forecast at $10.00 and the lowest ACIU stock price forecast at $10.00.

The Wall Street analyst predicted that Ac Immune Sa's share price could reach $10.00 by Jul 11, 2023. The average Ac Immune Sa stock price prediction forecasts a potential upside of 289.11% from the current ACIU share price of $2.57.

What is ACIU's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: ACIU) Ac Immune Sa's current Earnings Per Share (EPS) is -$0.89. On average, analysts forecast that ACIU's EPS will be -$1.01 for 2022, with the lowest EPS forecast at -$1.05, and the highest EPS forecast at -$0.94. On average, analysts forecast that ACIU's EPS will be -$0.33 for 2023, with the lowest EPS forecast at -$0.94, and the highest EPS forecast at $0.63. In 2024, ACIU's EPS is forecast to hit -$0.33 (min: -$1.04, max: $0.16).

What is ACIU's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: ACIU) forecast ROE is -13.64%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.